噻托溴铵吸入剂联合沙美特罗替卡松粉吸入剂对中重度慢性阻塞性肺疾病患者稳定期的肺功能及预后的影响

发布时间：2018-05-11 20:35

本文选题：噻托溴铵 + 沙美特罗替卡松　；参考：《中国临床药理学杂志》2017年12期

【摘要】：目的探讨噻托溴铵吸入剂联合沙美特罗替卡松粉吸入剂对中重度慢性阻塞性肺(COPD)疾病患者稳定期的肺功能及预后的影响。方法将80例中重度COPD患者随机分为对照组40例和试验组40例。对照组予以沙美特罗替卡松粉吸入剂进行治疗,50μg/500μg,每天早晚各1次;试验组在对照组的基础上加用噻托溴铵吸入剂治疗,18μg,每天1次,睡前吸入,疗程为3个月。比较2组患者的临床疗效、肺功能指标、6 min步行试验、呼吸困难评分以及药物不良反应发生率。结果治疗后,试验组和对照组总有效率分别为87.50%(35/40例)和67.50%(27/40例),差异有统计学意义(P0.05);治疗后试验组和对照组的一秒钟用力呼气容积(FEV1)分别为(2.22±0.27),(1.80±0.35)L;最大肺活量(FVC)分别为(3.31±0.40),(2.97±0.59)L;FEV1/FVC分别为(65.36±8.00)%,(56.97±8.61)%;6 min步行试验分别为(421.68±30.24),(401.26±31.27)m;呼吸困难评分分别为(1.35±0.29),(1.70±0.39)分,差异均有统计学意义(均P0.05)。2组患者药物不良反应主要为口干、恶心、声音嘶哑,试验组和对照组药物不良反应发生率分别为15.00%(6/40例)和10.00%(4/40例),差异无统计学意义(P0.05)。结论噻托溴铵吸入剂联合沙美特罗替卡松粉吸入剂可改善肺功能,临床疗效显著,且安全性高。
[Abstract]:Objective to investigate the effects of tiotropium bromide inhalation combined with salmeterol ticasone powder inhalation on pulmonary function and prognosis in patients with moderate and severe chronic obstructive pulmonary disease (COPD). Methods 80 patients with moderate and severe COPD were randomly divided into control group (n = 40) and trial group (n = 40). The control group was treated with salmeterolticasone powder inhalation 50 渭 g / 500 渭 g each morning and evening, and the experimental group was treated with thiotropium bromide inhalation for 18 渭 g, once a day, for 3 months before bedtime. The clinical efficacy, pulmonary function index, 6 min walking test, dyspnea score and incidence of adverse drug reactions were compared between the two groups. Results after treatment, The total effective rates of the test group and the control group were 87.50 / 35 / 40) and 67.50 / 27 / 40 respectively, the difference was statistically significant (P 0.05); after treatment, the forced expiratory volume and FEV1 of the test group and the control group were 2.22 卤0.27% 1.80 卤0.35 L respectively; the maximum vital capacity of FVCs was 2.31 卤0.40%; the FEV1FVC of the test group and the control group were 65.36 卤8.00% and 6.56 卤8.61 min, respectively, and the total effective rates of the test group and the control group were 2.31 卤0.40% and 2.97 卤0.59 L / L, respectively, and the FEV1FVC of the test group and the control group were 65. 36 卤8. 00 卤8. 61% and 1. 80 卤0. 35 L respectively. The scores of walking test were 421.68 卤30.24, the scores of dyspnea were 1.35 卤0.29 and 1.70 卤0.39, respectively, the scores of walking test were 401.26 卤31.27m, the scores of dyspnea were 1.35 卤0.29 and 1.70 卤0.39, respectively. The difference was statistically significant (the main adverse drug reactions were dry mouth, nausea, hoarseness, the incidence of adverse drug reactions in the test group and the control group were 15.00 / 40) and 10.00 / 40 / 40 respectively. There was no significant difference between the two groups (P 0.05). Conclusion tiotropium bromide inhaler combined with salmeterol ticasone powder can improve pulmonary function, and has significant clinical efficacy and high safety.
【作者单位】：义乌市中心医院呼吸二科;温州医科大学附属第二医院呼吸科;
【基金】：浙江省医药卫生科技计划基金资助项目(2013RCA039)
【分类号】：R563.9

【相似文献】